August 2019

Immunotherapies Show Promising Advancements in Small Cell Lung Cancer

August 13, 2019

Clinical Articles

Although chemotherapy remains the standard treatment for small cell lung cancer in first- and second-line settings, notable progress in immunotherapies have recently taken place, begging the question of how these agents will be optimized in this tumor type.

CAR T-Cell Therapy Poised to Become Routine Care in CLL

August 13, 2019

Clinical Articles

The initial pilot study of CTL019 in heavily pretreated CD19-positive hematologic malignancies demonstrated the feasibility of CAR T-cell therapy in patients with CLL. A presentation at the 2019 American Society of Gene & Cell Therapy Annual Meeting reported 2 cases of chemotherapy-resistant CLL, with ongoing follow- up at 8 years showing persistence of CAR-engineered T cells and sustained remission, as determined by flow cytometry and deep sequencing of immunoglobulin H rearrangements.

Safety, Feasibility Study Reveals Possible Benefit of Immune Cell Therapy in Pancreatic Cancer

August 13, 2019

Clinical Articles

Findings from a phase I study investigating the use of nonengineered T-cell therapy suggest that the therapy is safe and feasible in pancreatic cancer and may offer benefit to patients. The novel therapy targets the tumor-associated antigens PRAME, SSX2, MAGEA4, NY-ESO-1, and Survivin.

Expert Explores the Rationale for Liver-Directed Therapies in Metastatic NETs

August 15, 2019

Clinical Articles

Management of neuroendocrine liver metastases relies on many treatment modalities, ranging from surgery to ablation. Clinicians have in their armamentarium interventional radiology techniques that use regional and systemic treatments spanning a diverse group of biologic, cytotoxic, and targeted agents.

Strategies for Overcoming CDK4/6 Inhibition Emerge in ER+ Breast Cancer

August 13, 2019

Clinical Articles

Both cell cycle-specific and nonspecific mechanisms that lead to acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer have resulted in multiple promising agents and combinations for the second-line management of metastatic disease.

Although Barriers to Treating Brain Metastases Exist, Systemic Therapies Make Progress

August 15, 2019

Clinical Articles

The American Society of Clinical Oncology and Friends of Cancer Research have issued a joint research statement that broadens eligibility criteria affecting 2 patient subgroups: patients with treated/stable brain metastases and those with new, active, or progressive brain metastases.

Diagnostic and Therapeutic Modalities of PSMA-PET Emerge in Nonmetastatic Prostate Cancer

August 18, 2019

Clinical Articles

PET imaging modalities such as fluciclovine PET, choline PET, and more recently PSMA-PET are more sensitive in the detection of both soft tissue and bone metastases. These newer modalities have the potential to better identify patients who are eligible for targeted treatment of oligometastases with radiation or treatments more appropriate for immediate systemic androgen deprivation, according to Arjun V. Balar, MD.

Expanded Guidelines Offer Clearer Diagnosis for Classical, Special Variants of CMML

August 15, 2019

Clinical Articles

Recent guidelines highlight the need to distinguish chronic myelomonocytic leukemia from conditions similar to other myeloproliferative neoplasms, provide standardized diagnostic procedures, and outline therapeutic options for adult patients with CMML.

Approved Combinations and Novel Agents Expand Therapy Options Across Multiple Myeloma Settings

August 19, 2019

Clinical Articles

The addition of novel agents and combinations to the treatment of multiple myeloma, along with improvements in personalized therapy based on genetic profiles of individual patients, are propelling care forward with their potential for prolonging survival and deepening responses beyond those from the current standards of care.

New Quality Initiative for Patients With Advanced Lung Cancer Improves Care, Coordination

August 16, 2019

Clinical Articles

Twenty to 30 years ago, delivering a diagnosis of lung cancer to a patient was a difficult conversation to have for many oncologists. But that has given way to greater optimism today, according to Mark A. Socinski, MD.

CDK4/6 Inhibitor Combinations Could Have Lasting Benefits in ER+ Metastatic Breast Cancer

August 21, 2019

Clinical Articles

CDK4/6 inhibitors offer clear benefits in pro­gression-free survival, delayed time to chemotherapy, and overall survival in both pre and postmenopausal patients with estrogen receptor-positive metastatic breast cancer, said Angela DeMichele, MD, MSCE.

Practical Assessment Tools Guide Treatment Decisions in Geriatric Oncology

August 21, 2019

Clinical Articles

In a presentation at the 18th Annual International Congress on the Future of Breast Cancer® East, hosted by Physicians’ Education Resource®, LLC, in New York, Armin Shahrokni, MD, MPH, emphasized the importance of performing a comprehensive geriatric assessment for each patient to determine optimal treatment.